# A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

> **NCT05258747** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 70 (actual)

## Conditions studied

- Ovarian Cancer
- Breast Cancer

## Interventions

- **DRUG:** Olaparib tablets, 150 mg
- **DRUG:** Lynparza® (olaparib) tablets 150 mg

## Key facts

- **NCT ID:** NCT05258747
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-07
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-10-20
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05258747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05258747, "A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05258747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*